Related Experiment Videos
Exenatide efficacy and safety: a systematic review.
S L Norris1, N Lee, S Thakurta
1Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, OR 97281, USA. norriss@ohsu.edu
Diabetic Medicine : a Journal of the British Diabetic Association
|September 2, 2009
Summary
Exenatide effectively lowers blood glucose (HbA1c) in poorly controlled diabetes, similar to other oral agents or insulin. This diabetes medication also aids in weight loss, though nausea is a common side effect.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia.
- Effective glycemic control is crucial in managing diabetes and preventing complications.
- Exenatide, a glucagon-like peptide-1 receptor agonist, offers a therapeutic option for type 2 diabetes.
Purpose of the Study:
- To evaluate the efficacy, effectiveness, and safety of exenatide compared to oral glucose-lowering agents and insulin therapy.
- To assess exenatide's impact on glycemic control, specifically glycated hemoglobin (HbA1c) levels.
- To determine the effect of exenatide on body weight and identify common adverse events.
Main Methods:
- A systematic literature search was conducted across multiple databases.
- Data from 17 identified studies were qualitatively synthesized.
- Random effects meta-analysis was employed where appropriate to pool estimates.
Main Results:
- Exenatide 10 mcg twice daily significantly reduced HbA1c by approximately 1.0% in patients with poorly controlled diabetes on oral agents.
- Glycemic control with exenatide was comparable to insulin therapy over 16-52 weeks.
- Exenatide was associated with significant weight loss (1.0-6.0 kg) and nausea was the most frequent adverse event.
Conclusions:
- Exenatide demonstrates comparable efficacy to other oral agents and insulin in improving glycemic control in poorly controlled type 2 diabetes.
- Weight reduction is a potential advantage of exenatide therapy.
- Further long-term studies in diverse populations are necessary to fully elucidate the benefit-risk profile of exenatide.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...